{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"33","upperLimit":"61","value":"47"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"60"}],"units":"Participants"}],"description":"Two-year progression-free survival rate was defined as the proportion of patients that were alive progression-free two years after registration into the study. Disease progression was assessed per modified RECIST criteria, and defined as at least a 20% increase in the sum of the longest diameters of target lesions, in either primary or nodal lesions, taking as reference the smallest sum longest diameter recorded since the baseline measurements, or the appearance of new lesions. Kaplan-Meier estimate of 2-year progression-free survival was calculated in the 60 eligible and treated patients.","dispersionType":"95% Confidence Interval","groups":[{"description":"* Cetuximab therapy: Patients receive an initial loading dose of cetuximab intravenously (IV) over 2 hours on day 1. Patients then receive cetuximab IV over 1 hour on days 8, 15, 22, 29, 36, 43, 50, and 57.\n* Chemoradiotherapy: Beginning on day 15 of cetuximab therapy, patients undergo radiotherapy once daily, 5 days a week, for at least 7 weeks. Patients also receive cisplatin IV over 1-2 hours on days 15, 36, and 57.\n* Cetuximab maintenance therapy: After the completion of chemoradiotherapy, patients continue to receive cetuximab IV over 1 hour once weekly for 6-12 months.","id":"OG000","title":"Cisplatin, C225, Radiation"}],"paramType":"NUMBER","populationDescription":"Eligible and treated","reportingStatus":"POSTED","timeFrame":"assessed every 3 months for 2 years","title":"2-year Progression-free Survival Rate","type":"PRIMARY","unitOfMeasure":"proportion of participants"}